VRCA, US92511W2070

Lake Street sets USD 9.00 target for Verrica Pharmaceuticals stock

Published on 10/18/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 5.86 million in the second quarter. Verrica Pharmaceuticals stock stood at USD 3.60 on October 16, 2026 versus USD 9.00.

Verrica milestones and valuation

Lake Street set a USD 9.00 price target for Verrica on October 1, 2026.
Second-quarter 2026 revenue reached USD 5.86 million against a GAAP net loss of USD 13.15 million.
Verrica Pharmaceuticals stock last stood at USD 3.60 on October 16, 2026, on Nasdaq.

VRCA, US92511W2070, Illustration mit AI erstellt.

Lake Street set a USD 9.00 price target for Verrica Pharmaceuticals while maintaining its Buy rating, according to The Globe and Mail on October 1, 2026. The analyst action puts Verrica's commercial dermatology business and clinical pipeline against a target more than twice the last Nasdaq quote.

Revenue and losses shape the case

Verrica reported revenue of USD 5.86 million and a GAAP net loss of USD 13.15 million for the second quarter of 2026, figures carried by The Globe and Mail. The same report said revenue had been USD 12.70 million in the year-earlier period, making the latest quarter a sharper test of YCANTH commercialization and spending discipline.

Cash stood at USD 11.20 million on June 30, 2026, while operating cash flow was negative USD 9.28 million for the second quarter. That combination leaves the clinical pipeline dependent on commercial execution and capital management rather than revenue growth alone.

What did the YCANTH data show?

Verrica announced on September 30, 2026, that it would present a pooled analysis of its CAMP-1 and CAMP-2 Phase 3 trials at two dermatology conferences, according to Enid News. The analysis showed complete clearance by Day 84 for 60.1 percent of patients receiving VP-102, compared with 19.9 percent for vehicle, with a hazard ratio of 4.06.

Three dated company milestones

On September 30, 2026, Verrica announced the YCANTH analysis with a 4.06 hazard ratio. On October 1, 2026, Lake Street maintained its Buy rating and set a USD 9.00 target. From October 15 through October 17, 2026, the company scheduled the same YCANTH analysis for presentation at the PeDRA Annual Conference.

Nasdaq valuation remains the reference

Verrica develops dermatology medicines, including YCANTH for molluscum contagiosum and VP-315 for basal cell carcinoma. Its last quoted Nasdaq price was USD 3.60 on October 16, 2026 at 4:00 p.m. ET. The 52-week Nasdaq range was USD 3.28 to USD 9.82, while market capitalization stood at USD 61.8 million on that date.

The further course of trading is shown by the continuously updated real-time quote of Verrica Pharmaceuticals stock.